key: cord-1040389-r7h95rw3
authors: Manabe, Toshie; Akatsu, Hiroyasu; Kotani, Kazuhiko; Kudo, Koichiro
title: Trends in clinical features of novel coronavirus disease (COVID-19): A systematic review and meta-analysis of studies published from December 2019 to February 2020
date: 2020-06-28
journal: Respir Investig
DOI: 10.1016/j.resinv.2020.05.005
sha: 99d41d31429a8a56a302edfcdab042f0aeac8904
doc_id: 1040389
cord_uid: r7h95rw3

BACKGROUND: Since novel coronavirus disease (COVID-19) emerged, various clinical features of COVID-19 have been reported. METHODS: We conducted a systematic review of published studies reporting the clinical features of COVID-19. Two investigators independently searched PubMed (December 2019–February 2020) for eligible articles. A meta-analysis was performed to measure the frequencies of clinical outcomes and symptoms of COVID-19. A stratified analysis was conducted according to the timeline of outbreak and exposure histories: Group I, most patients were exposed to the Hunan seafood wholesale market and lived in Wuhan, Hubei province; Group II, patients lived in Hubei province but were not directly exposed to the market; and Group III, patients lived outside Hubei. RESULTS: Thirteen studies, all from China, were eligible. The estimated mortality rate among all studies was 2.12%, but that in Group I was 8.66%. The incidence of acute respiratory distress syndrome in Group I was 20.00%. Both fever and cough were major symptoms, and their frequencies were higher in Group I than in Groups II and III, while the frequency of diarrhea in Group I was lower than that in Group III. The estimated frequency of dyspnea in Group I was 37.18%, while those in Groups II and III were 16.95% and 7.03%, respectively. CONCLUSIONS: The trends in the clinical features of COVID-19 changed from December 2019 to February 2020. During this observation period, as the infection continued to spread, the clinical conditions for majority of patients became less severe with the changes in the route of transmission.

respiratory syndrome coronavirus; WHO, World Health Organization Introduction 1 In December 2019, an acute respiratory illness, now known to be caused by a novel secondary outcome variables: distributions of sex, comorbidities, symptoms, and signs. 48 Studies were excluded based on the following criteria: (1) reporting of surveillance data, (2) 49 no reporting of outcome variables, (3) no clear determination of the epidemiological exposure 50 history of patients, and (4) ≤20 patients. 51 A stratified analysis was conducted according to the exposure history and the 52 timeline of the COVID-19 outbreak: Group I, most patients were exposed to the Hunan 53 seafood wholesale market in the initial stage of the outbreak; Group II, patients lived in 54 Hubei province but could not be linked to the Hunan seafood wholesale market or community 55 exposure after 1 January; and Group III, patients lived outside of Hubei province. 56 57 Data extraction 58 Two reviewers extracted the data independently. Articles retrieved in the search were 59 stored in a citation manager (EndNote X8; Thomson Reuters, New York, NY, USA). After 60 removing redundant articles, titles and abstracts and then full-text articles were investigated. 61 We extracted the following data: study design, observational period, study site, and 62 inclusion/exclusion criteria of each study. Outcome variables were extracted into predesigned 63 data collection forms. We verified data accuracy by comparing the collection forms of each 64 investigator; any discrepancies were resolved through discussion together with other authors. Throughout the meta-analysis, we calculated the prevalence of each outcome variable with 68 95% confidence intervals (CIs) using a random-effects model (generic inverse variance 69 method). To assess the prevalence of each variable among patients with COVID-19, the 70 standard error was calculated using the Agresti-Coull method [17] . Heterogeneity among the 71 original studies was evaluated using the I 2 statistic [18] . Publication bias was examined using 72 a funnel plot. For all analyses, significance levels were two-tailed, and p < 0.05 was 73 considered significant. All statistical tests were performed using Review Manager (RevMan) 74 ver. 5.3.5 (Cochrane Collaboration, Copenhagen, Denmark) [19] .

Of the 482 references screened, 13 studies [2, 6, 7, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] reported the outcome variables 79 (Fig. 1) . In these 13 studies, we identified 2397 patients with COVID-19, and all eligible 80 studies were reports from China. Among the 13 eligible studies, 3 [2, 6, 20] were identified as 81 Group I (n = 279), 3 [21] [22] [23] were identified as Group II (n = 1356), and 7 [7, [24] [25] [26] [27] [28] [29] were 82 identified as Group III (n=743) ( Table 1 ). Table 1 shows the characteristics of the included studies. The observational period 84 (initial to end of observation date) in the eligible studies for each group was 19 December 

103 Among the studies that reported patients' clinical outcomes, more than half of the 104 patients remained in hospitals at the end of the observational period, except one study in 105 Group I in which 14.6% of patients died and 68.3% were discharged [2] . The estimated case 106 fatality rate in all 13 eligible studies was 1.80% (95% CI, 0.47-3.14), while the estimated 107 case fatality rates in Groups I and II were 8.66% and 2.96%, respectively (Fig. 2 ). In Group 108 III, the mortality was reported in only one study (3 cases among 262 patients, 1.15%) [7] . I (Fig. 3) . The estimated frequencies of cardiac injury, renal injury, and shock were reported 115 only in Group I (estimated frequencies of 7.97%, 3.65%, and 6.29%, respectively), except 116 one study in Group II for shock (1.09%) [23] . The estimated frequencies of symptoms among all available studies and stratified groups are 120 shown in Table 3 (Table 3 ; Fig. S3ⅴ ). The estimated frequencies of headache, sore throat, and 132 diarrhea were lower in Group I (7.17%, 11.09%, and 4.91%, respectively) than in Group III (11.13%, 13.32%, and 6.06%, respectively) ( Table 3 ; Fig. S3ⅵ , S3ⅶ, S3ⅸ). The estimated 134 frequency of expectoration in Group III (29.21%) was the third highest among the observed 135 symptoms in Group III and higher than the estimated frequency of expectoration in Group I 136 (7.11%) ( Table 3 ; Fig. S3ⅷ ). The estimated frequencies of death and complications of ARDS, cardiac injury, and renal 142 injury as well as symptoms of dyspnea in the initial stage of the outbreak were higher than 143 those in the later times. These results indicated that at the time of the outbreak, the disease 144 severity was greater in the initial phase than at later times.

The previous studies mentioned that most affected patients were thought to be 146 workers in the Hunan seafood wholesale market in the initial time of the outbreak [2, 6] . In 147 the present study, although none of the studies mentioned the prevalence of workers in the 148 Hunan seafood wholesale market, the estimated frequency of male patients in Group I was 149 higher than that in Groups II and III. It seemed reasonable that the patients with COVID-19 150 during the initial period of the outbreak included many workers in the Hunan seafood 151 wholesale market. After that initial phase, most affected patients were no longer only linked to the Hunan seafood wholesale market, and the proportions of males and females became 153 similar. More importantly, the patients who had an exposure history to the Hunan seafood 154 wholesale market were not all of the patients in Group Ⅰ (Table 1 ). In particular, Wang et al.

155 [20] found that only 8.7% of patients were exposed to the Hunan seafood wholesale market. 156 The results indicated that human-to-human transmission was presumed to have occurred even 157 at the initial phase of the outbreak in China. Notably, our evaluation indicated that the 158 estimated case fatality was 8.66%, which is much higher than the crude fatality ratio in China 159 (3.6%) reported by the WHO as of 1 March 2020 [4] , and the estimated prevalence of ARDS 160 decreased over time from Groups I to III. These results indicated that the disease prognosis 161 was worse in the initial period than at the later phases of the COVID-19 outbreak in China. A 162 study reported that angiotensin converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 163 [30] , and men had a higher ACE level in their alveolar cells than women [31, 32] . In addition 164 to the exposure risk, it may be possible that the cause of the higher prevalence in male 165 patients in the early phase of the outbreak in China was that male sex contributed to the 166 severity of COVID-19.

Coronavirus mainly causes respiratory tract infections, and some strains have high 168 infectivity and mortality [33] . SARS-CoV-2 has at least 70% similarity in its genetic 169 sequence to SARS-CoV [28] . One report stated that the severity of some cases of COVID-19 170 mimicked that of SARS [23] , which affected 8098 people in 26 can contribute to reduce the severity of disease [26] . 194 As the timeline progressed from Group I to Groups II and III, the proportion of mild infection and reducing severity [43] .

In terms of comorbidities, the results of the present study indicated that hypertension, 209 cardiovascular disease, and diabetes can be risk factors for the severity of COVID-19. A 210 study among critically ill patients with COVID-19 in the US reported that the prevalence of 211 diabetes mellitus (58%) was the highest among those showing comorbidities, followed by 212 chronic kidney disease (21%) [44] . These heterogenetic results suggested that comorbidities IV: inverse variance method; 95% CI: 95% confidence interval. 

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China

World Health Organization. WHO Director-General's opening remarks at the media

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics of COVID-19 infection in Beijing

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group

Approximate is Better than "Exact" for Interval Estimation of Binomial Proportions

Measuring inconsistency in meta-analyses

Review Manager (RevMan) [Computer program] Version 5.3 Copenhagen: The Nordic Cochrane Center

Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China

Novel Coronavirus (2019-nCoV) Pneumonia

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series

Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2

Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study

High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa

Understanding of COVID-19 based on current evidence

Sex Differences in Comorbidity, Therapy, and Health Services' Use of Heart Failure in Spain: Evidence from Real-World Data

Return of the Coronavirus: 2019-nCoV

World Health Organization. WHO SARS Risk Assessment and Preparedness Framework

Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study Clin Infect Dis

Virulence evolution in response to anti-infection resistance: toxic food plants can select for virulent parasites of monarch butterflies

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

50 Wuhan or nearby, 30 (60) Close contact

90 Wuhan or infected patient

The authors have no conflicts of interest to declare.